Skip to main content
SpringerLink
Log in

Kardiovaskulärer Risikofaktor

Lipoprotein(a): Bei wem messen, was bei erhöhten Werten tun?

Lipoprotein (a) — what to do?

  • FORTBILDUNG . SCHWERPUNKT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Lipoprotein(a) ist ein Plasma-Lipoprotein, das in den letzten Jahren zunehmend als kardiovaskulärer Risikofaktor anerkannt wurde. Wer darauf getestet werden sollte und welche Therapieansätze aktuell zur Verfügung stehen, erfahren Sie im nachfolgenden Beitrag.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Koschinsky ML MSM. Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol 2004(15):167–74.

  2. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009;301(22):2331–9.

    Article  CAS  PubMed  Google Scholar 

  3. Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302(4):412–23.

    Article  CAS  PubMed  Google Scholar 

  4. Emdin CA, Khera AV, Natarajan P, et al. Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels. Journal of the American College of Cardiology 2016;68(25):2761–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Catapano AL, Graham I, Backer G de, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European heart journal 2016;37(39):2999–3058.

    Article  PubMed  Google Scholar 

  6. Waldmann E, Parhofer KG. Lipoprotein apheresis to treat elevated lipoprotein (a). Journal of lipid research 2016;57(10):1751–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein(a): A randomised, double-blind, placebo-controlled phase 1 study. The Lancet 2015;386(10002):1472–83.

    Article  CAS  Google Scholar 

  8. Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): Two randomised, double-blind, placebo-controlled, dose-ranging trials. The Lancet 2016;388(10057):2239–53.

    Article  CAS  Google Scholar 

  9. Afshar M, Kamstrup PR, Williams K, Sniderman AD, Nordestgaard BG, Thanassoulis G. Estimating the Population Impact of Lp(a) Lowering on the Incidence of Myocardial Infarction and Aortic Stenosis-Brief Report. Arteriosclerosis, thrombosis, and vascular biology 2016;36(12):2421–3.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik der Universität München Medizinische Klinik IV, Campus Großhadern, Marchioninistr. 15, D-81377, München, Deutschland

    Elisa Waldmann

Authors
  1. Elisa Waldmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elisa Waldmann.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Waldmann, E. Lipoprotein(a): Bei wem messen, was bei erhöhten Werten tun?. MMW - Fortschritte der Medizin 160, 46–49 (2018). https://doi.org/10.1007/s15006-018-0092-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-018-0092-1

Keywords

Search

Navigation